Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

AstraZeneca

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dave Mott, president and chief executive officer of AstraZeneca’s biologics business unit, MedImmune, has decided to leave the company at the end of July for personal reasons. Tony Zook, chief executive officer of AstraZeneca’s North American business and executive vice president of global marketing, has been appointed head of MedImmune on an interim basis until a permanent successor is named.
   
David Brennan, chief executive officer of AstraZeneca, said, “Under Dave Mott’s leadership, the team at MedImmune has built a unique capability to discover, develop and deliver innovative biologic treatments — an important element of AstraZeneca’s future strategy. We will continue to build on that strong platform, maximizing the potential of products in the MedImmune portfolio while delivering innovative new biological medicines and vaccines that treat and prevent disease.”



Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters